Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Løhmann, DJA, Asdahl, PH, Abrahamsson, J, Ha, S-Y, Jónsson, ÓG, Kaspers, GJL, Koskenvuo, M, Lausen, B, De Moerloose, B, Palle, J, Zeller, B, Sung, L & Hasle, H 2019, 'Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia' Cancer Medicine, bind 8, nr. 15, s. 6634-6643. https://doi.org/10.1002/cam4.2554

APA

Løhmann, D. J. A., Asdahl, P. H., Abrahamsson, J., Ha, S-Y., Jónsson, Ó. G., Kaspers, G. J. L., ... Hasle, H. (2019). Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia. Cancer Medicine, 8(15), 6634-6643. https://doi.org/10.1002/cam4.2554

CBE

Løhmann DJA, Asdahl PH, Abrahamsson J, Ha S-Y, Jónsson ÓG, Kaspers GJL, Koskenvuo M, Lausen B, De Moerloose B, Palle J, Zeller B, Sung L, Hasle H. 2019. Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia. Cancer Medicine. 8(15):6634-6643. https://doi.org/10.1002/cam4.2554

MLA

Vancouver

Author

Løhmann, Ditte J A ; Asdahl, Peter H ; Abrahamsson, Jonas ; Ha, Shau-Yin ; Jónsson, Ólafur G ; Kaspers, Gertjan J L ; Koskenvuo, Minna ; Lausen, Birgitte ; De Moerloose, Barbara ; Palle, Josefine ; Zeller, Bernward ; Sung, Lillian ; Hasle, Henrik. / Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia. I: Cancer Medicine. 2019 ; Bind 8, Nr. 15. s. 6634-6643.

Bibtex

@article{9ea6bb0efcc5458893bb4cffe19f00f4,
title = "Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia",
abstract = "BACKGROUND: Associations between body mass index (BMI), outcome, and leukemia-related factors in children with acute myeloid leukemia (AML) remain unclear. We investigated associations between pretherapeutic BMI, cytogenetic abnormalities, and outcome in a large multinational cohort of children with AML.METHODS: We included patients, age 2-17 years, diagnosed with de novo AML from the five Nordic countries (2004-2016), Hong Kong (2007-2016), the Netherlands and Belgium (2010-2016), and Canada and USA (1995-2012). BMI standard deviations score for age and sex was calculated and categorized according to the World Health Organization. Cumulative incidence functions, Kaplan-Meier estimator, Cox regression, and logistic regression were used to investigate associations.RESULTS: In total, 867 patients were included. The median age was 10 years (range 2-17 years). At diagnosis, 32 (4{\%}) were underweight, 632 (73{\%}) were healthy weight, 127 (15{\%}) were overweight, and 76 (9{\%}) were obese. There was no difference in relapse risk, treatment-related mortality or overall mortality across BMI groups. The frequency of t(8;21) and inv(16) increased with increasing BMI. For obese patients, the sex, age, and country adjusted odds ratio of having t(8;21) or inv(16) were 1.9 (95{\%} confidence interval (CI) 1.1-3.4) and 2.8 (95{\%} CI 1.3-5.8), respectively, compared to healthy weight patients.CONCLUSIONS: This study did not confirm previous reports of associations between overweight and increased treatment-related or overall mortality in children. Obesity was associated with a higher frequency of t(8;21) and inv(16). AML cytogenetics appear to differ by BMI status.",
author = "L{\o}hmann, {Ditte J A} and Asdahl, {Peter H} and Jonas Abrahamsson and Shau-Yin Ha and J{\'o}nsson, {{\'O}lafur G} and Kaspers, {Gertjan J L} and Minna Koskenvuo and Birgitte Lausen and {De Moerloose}, Barbara and Josefine Palle and Bernward Zeller and Lillian Sung and Henrik Hasle",
note = "{\circledC} 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",
year = "2019",
doi = "10.1002/cam4.2554",
language = "English",
volume = "8",
pages = "6634--6643",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "15",

}

RIS

TY - JOUR

T1 - Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia

AU - Løhmann, Ditte J A

AU - Asdahl, Peter H

AU - Abrahamsson, Jonas

AU - Ha, Shau-Yin

AU - Jónsson, Ólafur G

AU - Kaspers, Gertjan J L

AU - Koskenvuo, Minna

AU - Lausen, Birgitte

AU - De Moerloose, Barbara

AU - Palle, Josefine

AU - Zeller, Bernward

AU - Sung, Lillian

AU - Hasle, Henrik

N1 - © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

PY - 2019

Y1 - 2019

N2 - BACKGROUND: Associations between body mass index (BMI), outcome, and leukemia-related factors in children with acute myeloid leukemia (AML) remain unclear. We investigated associations between pretherapeutic BMI, cytogenetic abnormalities, and outcome in a large multinational cohort of children with AML.METHODS: We included patients, age 2-17 years, diagnosed with de novo AML from the five Nordic countries (2004-2016), Hong Kong (2007-2016), the Netherlands and Belgium (2010-2016), and Canada and USA (1995-2012). BMI standard deviations score for age and sex was calculated and categorized according to the World Health Organization. Cumulative incidence functions, Kaplan-Meier estimator, Cox regression, and logistic regression were used to investigate associations.RESULTS: In total, 867 patients were included. The median age was 10 years (range 2-17 years). At diagnosis, 32 (4%) were underweight, 632 (73%) were healthy weight, 127 (15%) were overweight, and 76 (9%) were obese. There was no difference in relapse risk, treatment-related mortality or overall mortality across BMI groups. The frequency of t(8;21) and inv(16) increased with increasing BMI. For obese patients, the sex, age, and country adjusted odds ratio of having t(8;21) or inv(16) were 1.9 (95% confidence interval (CI) 1.1-3.4) and 2.8 (95% CI 1.3-5.8), respectively, compared to healthy weight patients.CONCLUSIONS: This study did not confirm previous reports of associations between overweight and increased treatment-related or overall mortality in children. Obesity was associated with a higher frequency of t(8;21) and inv(16). AML cytogenetics appear to differ by BMI status.

AB - BACKGROUND: Associations between body mass index (BMI), outcome, and leukemia-related factors in children with acute myeloid leukemia (AML) remain unclear. We investigated associations between pretherapeutic BMI, cytogenetic abnormalities, and outcome in a large multinational cohort of children with AML.METHODS: We included patients, age 2-17 years, diagnosed with de novo AML from the five Nordic countries (2004-2016), Hong Kong (2007-2016), the Netherlands and Belgium (2010-2016), and Canada and USA (1995-2012). BMI standard deviations score for age and sex was calculated and categorized according to the World Health Organization. Cumulative incidence functions, Kaplan-Meier estimator, Cox regression, and logistic regression were used to investigate associations.RESULTS: In total, 867 patients were included. The median age was 10 years (range 2-17 years). At diagnosis, 32 (4%) were underweight, 632 (73%) were healthy weight, 127 (15%) were overweight, and 76 (9%) were obese. There was no difference in relapse risk, treatment-related mortality or overall mortality across BMI groups. The frequency of t(8;21) and inv(16) increased with increasing BMI. For obese patients, the sex, age, and country adjusted odds ratio of having t(8;21) or inv(16) were 1.9 (95% confidence interval (CI) 1.1-3.4) and 2.8 (95% CI 1.3-5.8), respectively, compared to healthy weight patients.CONCLUSIONS: This study did not confirm previous reports of associations between overweight and increased treatment-related or overall mortality in children. Obesity was associated with a higher frequency of t(8;21) and inv(16). AML cytogenetics appear to differ by BMI status.

U2 - 10.1002/cam4.2554

DO - 10.1002/cam4.2554

M3 - Journal article

VL - 8

SP - 6634

EP - 6643

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 15

ER -

ID: 59096832